KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$18.2 million.

  • Emergent BioSolutions' Change in Accured Expenses fell 96.74% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.1 million, marking a year-over-year decrease of 1155.41%. This contributed to the annual value of -$18.2 million for FY2024, which is 67.32% up from last year.
  • Per Emergent BioSolutions' latest filing, its Change in Accured Expenses stood at -$18.2 million for FY2024, which was up 67.32% from -$55.7 million recorded in FY2023.
  • Emergent BioSolutions' Change in Accured Expenses' 5-year high stood at $21.8 million during FY2020, with a 5-year trough of -$66.7 million in FY2022.
  • For the 3-year period, Emergent BioSolutions' Change in Accured Expenses averaged around -$46.9 million, with its median value being -$55.7 million (2023).
  • In the last 5 years, Emergent BioSolutions' Change in Accured Expenses soared by 244.37% in 2020 and then tumbled by 625.00% in 2022.
  • Emergent BioSolutions' Change in Accured Expenses (Yearly) stood at $21.8 million in 2020, then crashed by 142.20% to -$9.2 million in 2021, then tumbled by 625.00% to -$66.7 million in 2022, then climbed by 16.49% to -$55.7 million in 2023, then soared by 67.32% to -$18.2 million in 2024.